Development of an inactivated vaccine candidate for SARS-CoV-2
Top Cited Papers
Open Access
- 3 July 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6499) , 77-81
Abstract
Vaccine candidate tested in monkeys: Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent race to develop a vaccine. Gao et al. report preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies. The researchers obtained multiple SARS-CoV-2 strains from 11 hospitalized patients across the world and then chemically inactivated the harmful properties of the virus. Animals were immunized with one of two vaccine doses and then inoculated with SARS-CoV-2. Those that received the lowest dose showed signs of controlling the infection, and those receiving the highest dose appeared more protected and did not have detectable viral loads in the pharynx or lungs at 7 days after infection. The next steps will be testing for safety and efficacy in humans. Science , this issue p. 77Keywords
All Related Versions
Funding Information
- National key research and development program (2020YFA0707500)
- Ten Thousand Talent Program and the NSFS Innovative Research Group (81921005)
This publication has 25 references indexed in Scilit:
- Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-CoronavirusFrontiers in Microbiology, 2019
- ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated dataMethods in Ecology and Evolution, 2016
- Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2015
- IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood PhylogeniesMolecular Biology and Evolution, 2014
- Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoringVaccine, 2009
- Lung pathology of fatal severe acute respiratory syndromeThe Lancet, 2003
- On the analysis of psychometric functions: The Spearman-Kärber methodPerception & Psychophysics, 2001
- Inactivated poliovirus vaccine: past and present experienceVaccine, 1996